Cargando…
13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against pseudomonas Aeruginosa (psa) from Patients with Cystic Fibrosis (CF)
BACKGROUND: CF acute pulmonary exacerbations are often caused by PSA, including multi-drug resistant strains. Optimal antibiotic therapy is required to return lung function and should be guided by in vitro susceptibility results. There are sparse data on the performance of Etest relative to referenc...
Autores principales: | Lasko, Maxwell J, Huse, Holly, Kuti, Joseph L, Nicolau, David P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776041/ http://dx.doi.org/10.1093/ofid/ofaa417.012 |
Ejemplares similares
-
Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis
por: Lasko, Maxwell J., et al.
Publicado: (2021) -
1602. Comparative Activity of Ceftolozane-Tazobactam (C/T) and Ceftazidime-Avibactam (CZA) against Pseudomonas aeruginosa (PSA) from Patients with Cystic Fibrosis (CF)
por: Lasko, Maxwell J, et al.
Publicado: (2020) -
1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
por: Ying, Yun, et al.
Publicado: (2020) -
1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020) -
2166. Performance Study on the New ETEST® Piperacillin/Tazobactam (P/T) MIC Strip
por: Martelin, Roland, et al.
Publicado: (2019)